Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

163 Press Releases
DateTitleCompany
25 Sep 14 BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership Takeda Pharmaceutical,
Published by
Business Wire
19 Jun 14 Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe Takeda Pharmaceutical Company Limited,
Published by
Business Wire
16 May 14 Orteronel Plus Prednisone Improved Progression Free Survival in Men With Chemotherapy-Naïve Metastatic Castration Resistant Prostate Cancer in Phase 3 Study Takeda Pharmaceutical Company Limited,
Published by
Business Wire
18 Mar 14 Takeda Appoints Giles Platford Head of Emerging Markets Takeda Pharmaceuticals International,
Published by
PR Newswire
03 Mar 14 Sunovion and Takeda Announce Results from a New Study Showing Maintenance Treatment with Lurasidone Reduced the Risk of Relapse in Adults with Schizophrenia Sunovion & Takeda
29 Jan 14 Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia Dainippon Sumitomo Pharma and Takeda
27 Dec 13 Takeda Announces Termination of Fasiglifam (TAK-875) Development Takeda Pharmaceutical Company Limited,
Published by
Business Wire
15 Oct 13 Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone – A New Atypical Antipsychotic treatment for Adults with Schizophrenia Takeda Pharmaceuticals International GmbH
23 Sep 13 NORGINE AND TAKEDA ANNOUNCE THE NEW DRUG APPLICATION APPROVAL OF OBLEAN® (cetilistat) TABLETS 120MG IN JAPAN Norgine and Takeda Pharmaceutical Company Limited,
Published by
Pharmiweb.com
12 Sep 13 First Country in Europe launches LATUDA® (lurasidone) - a New Atypical Antipsychotic for Adults with Schizophrenia Takeda Pharmaceuticals International GmbH
11 Sep 13 First Country in Europe launches LATUDA® (lurasidone) - a New Atypical Antipsychotic for Adults with Schizophrenia Takeda Pharmaceuticals International GmbH
05 Sep 13 Takeda EXAMINE Study Takeda,
Published by
Reynolds Mackenzie
01 Aug 13 Takeda Receives Marketing Authorization from China's CFDA for New Type 2 Diabetes Therapy NESINA (alogliptin) Takeda Pharmaceutical,
Published by
Pharmiweb.com
26 Jul 13 Takeda Announces Unblinding of Phase 3 Study of Orteronel in Patients with Metastatic, Castration-Resistant Prostate Cancer That Progressed Post-Chemotherapy Based on Interim Analysis Takeda Pharmaceutical Company Limited,
Published by
Business Wire
03 Jun 13 ASCO Presentation Highlights Results of Single Agent oral MLN9708 in Heavily Pretreated Patients with Relapsed and/or Refractory Multiple Myeloma Takeda Pharmaceutical Company Limited,
Published by
Business Wire
03 Jun 13 Takeda Highlights Data from Clinical Trial Examining the Use of ADCETRIS® (Brentuximab Vedotin) in Pediatric Patients Takeda,
Published by
Pharmiweb.com
24 May 13 Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma Takeda Pharmaceutical Company Limited,
Published by
Business Wire
09 May 13 Takeda Appoints New President for Millennium: The Takeda Oncology Company Takeda,
Published by
PharmiWeb.com
08 May 13 Takeda to Acquire Inviragen, Inc. Takeda
24 Apr 13 Takeda Submits a New Drug Application for the Fixed-Dose Combination of Azilva® and Amlodipine Besylate in Japan Takeda Pharmaceutical Company Limited
29 Mar 13 Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer Millennium: The Takeda Oncology Company,
Published by
Business Wire
11 Mar 13 Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union Takeda Pharmaceutical Company Limited
04 Mar 13 Industry Leaders and Academic Researchers Come Together for Innovative Accelerating Cancer Cures Research Symposium Millennium: The Takeda Oncology Company,
Published by
Business Wire
24 Feb 13 Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection Affymax Inc. & Takeda Pharmaceutical Company Limited,
Published by
Business Wire
24 Jan 13 New England Journal of Medicine Publishes Pivotal Trial Data for OMONTYS® (peginesatide) Injection for Treatment of Anemia in Adult Chronic Kidney Disease Patients on Hemodialysis Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
23 Jan 13 Multiple Myeloma Research Foundation (MMRF) Names Millennium Collaborator of the Year Millennium: The Takeda Oncology Company,
Published by
Business Wire
07 Jan 13 Takeda and Affymax Announce Supply Agreement for OMONTYS® (Peginesatide) Injection with DSI Renal Takeda Pharmaceuticals U.S.A. Inc. and Affymax Inc.,
Published by
Business Wire
03 Jan 13 Affymax and Takeda Announce Permanent J-Code for OMONTYS® (peginesatide) Injection is in Effect Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
11 Dec 12 Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis Millennium: The Takeda Oncology Company,
Published by
Business Wire
11 Dec 12 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
Advertising